Bevacizumab/triamcinoloneEndophthalmitis: 14 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1960卷 / 1期

关键词：

D O I：

10.1007/s40278-023-40933-1

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：105 / 105

相关论文

共 50 条

[31] Aflibercept/bevacizumab/ranibizumabEndophthalmitis: 12 case reports
Reactions Weekly, 2023, 1971 (1) : 18 - 18
[32] Aflibercept/bevacizumab/ranibizumabEndophthalmitis: 4 case reports
Reactions Weekly, 2023, 1952 (1) : 34 - 34
[33] Bevacizumab/paclitaxelVarious toxicities: 4 case reports
Reactions Weekly, 2021, 1844 (1) : 94 - 94
[34] Bevacizumab/ixabepiloneNeuropathy and mucositis: 2 case reports
Reactions Weekly, 2015, 1580 (1) : 66 - 66
[35] Bevacizumab/paclitaxelProteinuria and mucositis: 2 case reports
Reactions Weekly, 2025, 2048 (1) : 81 - 81
[36] Bevacizumab/cetuximabDrug resistance: 2 case reports
Reactions Weekly, 2020, 1799 (1) : 98 - 98
[37] Bevacizumab/dexamethasoneVarious toxicities: 3 case reports
Reactions Weekly, 2018, 1713 (1) : 64 - 64
[38] Bevacizumab/antineoplasticsVarious toxicities: 19 case reports
Reactions Weekly, 2013, 1447 (1) : 11 - 11
[39] Bevacizumab/irinotecanVarious toxicities: 13 case reports
Reactions Weekly, 2014, 1498 (1) : 10 - 10
[40] Bevacizumab/irinotecanNausea and vomiting: 2 case reports
Reactions Weekly, 2017, 1644 (1) : 57 - 57

← 1 2 3 4 5 →